Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug
More than three years after raising a $45 million B round to get its lead drug into the clinic for wet age-related macular degeneration, two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
